Zobrazeno 1 - 10
of 1 409
pro vyhledávání: ''
Autor:
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk
Autor:
Qiong Lyu, Jian Zhang, Peng Luo, Ting Wei, Weimin Ding, Linlang Guo, Weiliang Zhu, Qiongyao Wang, Manming Cao
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Cancer Medicine
Cancer Medicine
Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify patients
Publikováno v:
Future Oncology. 17:2759-2768
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiat
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Publikováno v:
Clinical and Translational Oncology. 23:2171-2180
APL patients have recurrent alterations in FLT3, WT1, NRAS and KRAS. Gene mutations have a strong potential for involvement in pathogenesis and may have potential effects on the clinical manifestations. Gene mutations may even be associated with earl
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
S. Hazra, Zhong-Zhe Lin, Yen-Hsun Chen, Ghassan K. Abou-Alfa, Suvajit Sen, Tim Meyer, Rebecca A. Miksad, Jillian Youkstetter, Ann-Lii Cheng, Stefano Kim, Anthony B. El-Khoueiry, Irfan Cicin, Heinz-Josef Klümpen, Robin Kate Kelley
Publikováno v:
British journal of cancer, 126(4), 569-575. Nature Publishing Group
British Journal of Cancer, vol 126, iss 4
British Journal of Cancer, vol 126, iss 4
Background Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff7d7aa6f342671f87fffbc132a97bdb
https://pure.amc.nl/en/publications/efficacy-and-safety-of-cabozantinib-for-patients-with-advanced-hepatocellular-carcinoma-based-on-albuminbilirubin-grade(6723e70d-57fc-46f8-80b0-a3460e6124cc).html
https://pure.amc.nl/en/publications/efficacy-and-safety-of-cabozantinib-for-patients-with-advanced-hepatocellular-carcinoma-based-on-albuminbilirubin-grade(6723e70d-57fc-46f8-80b0-a3460e6124cc).html
Autor:
Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Shinya Tani, Satoshi Baba, Takahisa Furuta, Hiroaki Miyajima, Junko Murai, Moriya Iwaizumi, Yasushi Hamaya, Yves Pommier, Haruhiko Sugimura, Satoshi Osawa, Takahiro Uotani, Ken Sugimoto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognos
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Autor:
Chenlu Zhang, Xiaojing Xu, Shengchao Wu, Wei Guo, Fei Huang, Yiyi Yu, Tianshu Liu, Mengling Liu, Li Liang, Minna Shen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background The aim of this study was to explore the utility of circulating free DNA (cfDNA) in the evaluation of clinical tumor burden and survival in Chinese patients with metastatic colorectal cancer (mCRC) and to preliminarily summarize some metas